Purifying Pancreatic Endocrine Cells via CD200 Ligand Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying pancreatic endocrine cells derived from human embryonic stem cells are inefficient, lacking reliable techniques to isolate and enrich these cells for therapeutic applications, such as treating insulin-dependent diabetes.
Innovation Solution
A method involving exposure of pluripotent stem cell-derived populations to a ligand binding to the CD200 cell surface marker, followed by separation to purify pancreatic endocrine cells, which express chromogranin A and are capable of functioning like human pancreatic islet cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional purification methods are used for pancreatic endocrine cells, then the process is simpler, but the purification efficiency and cell enrichment are insufficient
Solution Approach 1:
The patent utilizes changes in cell surface marker expression parameters during differentiation to enable purification. Specifically, pancreatic endocrine cells express CD200 and chromogranin A markers at distinct levels compared to other cell types, allowing for parameter-based separation through flow cytometry or magnetic-activated cell sorting (MACS) techniques
Solution Approach 2:
The patent replaces conventional mechanical or manual purification methods with ligand-based binding mechanisms. By using antibodies or other ligands that specifically bind to CD200 or chromogranin A markers on pancreatic endocrine cells, the purification process achieves higher efficiency through molecular recognition rather than physical separation methods
2Manufacturing precision
If no specific cell surface marker is used, then the method is easier to implement, but the purification precision and cell specificity are insufficient
Solution Approach 1:
The patent introduces cell surface markers (CD200, chromogranin A) as intermediary targets for purification. These markers serve as molecular intermediaries that enable specific recognition and isolation of pancreatic endocrine cells from mixed cell populations through ligand binding, achieving high precision without requiring direct manipulation of cell properties
Solution Approach 2:
The patent exploits parameter changes in marker expression during cellular differentiation. Pancreatic endocrine cells undergo differentiation that results in specific expression patterns of CD200 and chromogranin A, allowing purification based on these dynamic parameter changes rather than static cell properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively purifies pancreatic endocrine cells, enhancing their functionality and viability for potential therapeutic use in treating diabetes by isolating cells that express specific markers like CD200 and chromogranin A.
Implementation Method 1
exposing a population of cells derived from pluripotent stem cells comprising a pancreatic endocrine cell to a ligand which binds to a cell surface marker expressed on the pancreatic endocrine cell, wherein the cell surface marker is CD200
Data Source
Figure 1
Figure 2
AI summary
The present disclosure relates to compositions and methods comprising cell surface markers for hES-derived cells, in particular, endoderm lineage cells including pancreatic endoderm-type cells, derived from hES cells.